These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 18075834)
1. Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. Al-Adnani M; Williams S; Anderson J; Ashworth M; Malone M; Sebire NJ Fetal Pediatr Pathol; 2007; 26(4):193-7. PubMed ID: 18075834 [TBL] [Abstract][Full Text] [Related]
2. A new molecular variant of desmoplastic small round cell tumor: significance of WT1 immunostaining in this entity. Murphy AJ; Bishop K; Pereira C; Chilton-MacNeill S; Ho M; Zielenska M; Thorner PS Hum Pathol; 2008 Dec; 39(12):1763-70. PubMed ID: 18703217 [TBL] [Abstract][Full Text] [Related]
3. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Carpentieri DF; Nichols K; Chou PM; Matthews M; Pawel B; Huff D Mod Pathol; 2002 Oct; 15(10):1080-6. PubMed ID: 12379755 [TBL] [Abstract][Full Text] [Related]
4. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762 [TBL] [Abstract][Full Text] [Related]
5. WT1 protein expression in childhood acute leukemia. Kerst G; Bergold N; Gieseke F; Coustan-Smith E; Lang P; Kalinova M; Handgretinger R; Trka J; Müller I Am J Hematol; 2008 May; 83(5):382-6. PubMed ID: 18161786 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086 [TBL] [Abstract][Full Text] [Related]
7. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia. Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653 [TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058 [TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia. Spanaki A; Linardakis E; Perdikogianni C; Stiakaki E; Morotti A; Cilloni D; Kalmanti M Leuk Res; 2007 Apr; 31(4):570-2. PubMed ID: 16876863 [TBL] [Abstract][Full Text] [Related]
10. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan]. Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800 [TBL] [Abstract][Full Text] [Related]
11. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor. Zhao C; Bratthauer GL; Barner R; Vang R Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194 [TBL] [Abstract][Full Text] [Related]
13. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450 [TBL] [Abstract][Full Text] [Related]
14. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768 [TBL] [Abstract][Full Text] [Related]
15. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. Ishikawa Y; Kiyoi H; Naoe T Leuk Res; 2011 May; 35(5):685-8. PubMed ID: 21256590 [TBL] [Abstract][Full Text] [Related]
17. Podocalyxin: a marker of blasts in acute leukemia. Kelley TW; Huntsman D; McNagny KM; Roskelley CD; Hsi ED Am J Clin Pathol; 2005 Jul; 124(1):134-42. PubMed ID: 15923169 [TBL] [Abstract][Full Text] [Related]
18. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857 [TBL] [Abstract][Full Text] [Related]